A Phase I Trial of Oxaliplatin, Irinotecan, and S‐1 Combination Therapy (OX‐IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403)

LESSONS LEARNED: Because S‐1 is orally administered, OX‐IRIS does not necessitate the continuous infusion of 5‐FU and is more convenient. The recommended dose of OX‐IRIS was determined to be level −1 (oxaliplatin, 65 mg/m(2); irinotecan, 100 mg/m(2); S‐1, 80 mg/m(2)), which has manageable safety and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawamoto, Yasuyuki, Nakatsumi, Hiroshi, Harada, Kazuaki, Muranaka, Tetsuhito, Ishiguro, Atsushi, Kobayashi, Yoshimitsu, Hayashi, Hideyuki, Yuki, Satoshi, Sawada, Kentaro, Yagisawa, Masataka, Nakano, Shintaro, Sakamoto, Naoya, Komatsu, Yoshito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488776/
https://www.ncbi.nlm.nih.gov/pubmed/34050586
http://dx.doi.org/10.1002/onco.13838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488776/
https://www.ncbi.nlm.nih.gov/pubmed/34050586
http://dx.doi.org/10.1002/onco.13838

Ejemplares similares